Navigation Links
Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Date:5/16/2008

MicroRNAs as Potential Biomarkers -- for Lung Cancer Diagnosis and Identification of Tumor Origin in Patients With Cancer of Unknown Primary

(CUP) MicroRNAs Objectively Identify Cancer Types With High Sensitivity and Specificity and Could Revolutionize Diagnosis and Treatment of Cancer

Results of microRNA Signature to Identify Tissue Origin Demonstrate

Accuracy Exceeding 90% and Specificity of 99%

REHOVOT, Israel and JERSEY CITY, New Jersey, May 16 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd. (Nasdaq:ROSG), a leader in the development of microRNA-based diagnostics and therapeutics, today announced that it will present multiple posters at the upcoming ASCO annual meeting in Chicago. The company also has three publication only abstracts available on ASCO's website. The event will take place from May 30 to June 3 at the McCormick Place, Chicago, Illinois.

Presented posters:

1. "MicroRNA signature identifies tissue origin of primary and metastatic tumors"; Tuesday, June 03, 8:00AM - 12:00PM; Hall S102a, abstract # 11028.

Each year approximately 70,000 patients in the United States are diagnosed with cancer of unknown primary (CUP). Accurately identifying the origin of a metastasis can be critical in guiding treatment decisions. Rosetta Genomics' scientists have designed a classifier which assigns a primary site to a cancer sample based on the microRNA expression in the sample. The overall sensitivity of this classifier is approximately 85%, with two-thirds of the samples being classified with high-confidence, reaching accuracy exceeding 90% and specificity of 99%.

2. "Differential microRNA expression in pleural mesothelioma: Implications for early detection and prognostication"; Tuesday, June 03; 8:00AM - 12:00PM; Hall S102a; abstract # 11027. Malignant mesothelioma (MM) is an asbestos induced pleural neoplasm with a median survival (MS) of 12 months, and relatively little is known about the molecular events that lead to the development of this highly aggressive disease. Using Rosetta Genomics' unique microRNA platform, Dr. Harvey Pass, NYU School of Medicine, examines whether there are distinct mir profiles between MM and normal mesothelium, and whether mirs are associated with demographic/prognostic features in MM patients.

3. "MicroRNAs as powerful diagnostic tools for the differential diagnosis of lung tumors"; Sunday, June 01; 8:00AM - 12:00PM; Hall S A1; abstract # 11112. Lung cancer is a heterogeneous disease with many histological subtypes, further complicated by the frequent occurrence of lung metastases from various tumor origins. Therefore, determining the correct diagnosis of any lung tumor often poses a difficult diagnostic challenge that may have very significant therapeutic implications. This poster will detail the use of microRNAs for differentiating between different primary lung tumors and metastases to the lung.

4. "MicroRNA expression profile identifies origin of tumors in the liver"; Tuesday, June 03; 8:00AM - 12:00PM; Hall S102a; abstract # 11026. The distinction of liver metastasis from hepatocellular carcinoma (HCC) and determining its tissue origin is a frequent problem in oncology, especially since liver metastases, and particularly adenocarcinoma, may mimic the morphology and immunoexpression of hepatocellular carcinoma. Such distinction has significant therapeutic and prognostic implications. In the present study, Rosetta Genomics and collaborators use microRNAs as biomarkers for tissue identification to distinguish between HCC and metastatic tumors in the liver.

Publication only abstracts:

5. "MicroRNAs as specific biomarkers for distinguishin
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
2. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
6. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
9. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... April 27, 2016 Tie-up with ... initiative to save newborns   Fortis ... & newborns in collaboration with Breast Milk Foundation (BMF), a ... Pasteurized Human Milk Bank, ,Amaara, in Delhi-NCR today. This non-profit ... source for infants and should be available to babies deprived ...
(Date:4/27/2016)... YORK , April 27, 2016 ... OASM ), a developer of a new generation ... announced positive overall survival results for Paclical/Apealea in ... of 789 patients with epithelial ovarian cancer. These ... groups: Paclical/Apealea in combination with carboplatin versus Taxol ...
(Date:4/26/2016)... Diplomat Pharmacy, Inc. (NYSE: DPLO) is pleased ... Pharm D., to Vice President of Education and Quality. ... will continue to lead and oversee Diplomat University, an ... and training to Diplomat employees and external professionals on ... also houses the quality assurance department, which focuses on ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... In an article ... shares her enthusiasm for Botox and lip injections, which she underwent in order to ... Coachella Valley Music and Arts Festival. The article explains that Ms. Mirmelli’s situation is ...
(Date:4/29/2016)... ... , ... Our bodies are bombarded daily by environmental and lifestyle factors that ... is to adopt a more healthful diet, but too many people think that food ... Nutritionist and the creator of the Newport Beach Cleanse and 14-Day Eating Plan, disagrees ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House announced ... loans, more information about their loan terms and accounts, and more protections for ... including federal and private loans, has reached $1.3 trillion, with 43 million Americans ...
(Date:4/29/2016)... ... ... Spine Team Texas, a comprehensive spine physician group specializing in the treatment ... been invited to be a featured speaker at the Texas Society of the American ... 2016. , Dr. R. Scott McPherson, a physical medicine and rehabilitation specialist, will ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... Canadian Celiac Association (CCA), is pleased to announce the launch of the ... nutritional articles, recipes, and more. The purpose of the GFCP Scoop ...
Breaking Medicine News(10 mins):